Prodrugs pp 1347-1357 | Cite as

Case Study: Tenofovir Disoproxil Fumarate: An Oral Prodrug of Tenofovir

  • Maria Fardis
  • Reza Oliyai
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

Tenofovir (PMPA) is a novel nucleotide analog that belongs to the class of acyclic nucleoside phosphonates. The potential antiviral effect of tenofovir was demonstrated by Hol and DeClercq (Balzarini et al., 1993). In this class of compounds, the ribose-phosphate group is replaced with the isopolar phosphonopropyl ether functionality. Tenofovir is recognized by host kinases and is phosphorylated in situ to the virologically active tenofovir diphosphate. Tenofovir diphosphate inhibits the human immunodeficiency virus (HIV-1 and HIV-2) DNA polymerase (reverse transcriptase) in addition to other viral DNA polymerases (Naesens et al., 1997). This inhibition results in DNA chain termination and impairment of viral replication. The IC50 values of tenofovir inhibition of HIV-1 reverse transcriptase is between 0.04 and 8.5 µM (Viread package insert).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arimilli M, Kim C, and Bischofberger N. Synthesis, In Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Prodrugs. Antivir Chem Chemother 1997; 8:557–564Google Scholar
  2. Balzarini J, Holý A, Jindrich J, Naesens L, Snoeck R, Schols D, and De Clercq E. Differential Antiherpesvirus and Antiretrovirus Effects of the (S) and (R) Enantiomers of Acyclic Nucleoside Phosphonates: Potent and Selective In Vitro and In Vivo Antiretrovirus Activities of (R)-9-(2-Propyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993; 37:332–338PubMedGoogle Scholar
  3. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, and Lietman PS. Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in HIV-1 Infected Adults. Antimicrob Agents Chemother. 2001; 45:2733–2739PubMedCrossRefGoogle Scholar
  4. Cundy KC. Clinical Anti-HIV Activity of Tenofovir Disoproxil Fumarate Correlates with Intracellular Drug Levels (Abstract 318). 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, Portugal, 1999. Poster 318Google Scholar
  5. Cundy KC, Sueoka CM, Lynch GR, Griffin L, Lee WA, and Shaw J-P. Pharmacokinetics and Bioavailability of the Anti-human Immunodeficiency Virus Nucleotide Analog 9-[(R)-2-(Phosphonomethoxy)propyl]adenine (PMPA) in Dogs. Antimicrob Agents Chemother 1998; 42:687–690PubMedGoogle Scholar
  6. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang K, Cundy C, Rooney JF, Hellmann NS, Safrin S, and Kahn JO. Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, A Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults. Antimicrob Agents Chemother 1998; 42:2380–2384PubMedGoogle Scholar
  7. Flaherty JF, Kearney BP, Wolf JJ, Sayre JR, and Coakley DF. A Multiple-Dose, Randomized, Crossover Drug Interaction Study between Tenofovir DF and Efavirenz, Indinavir, or Lopinavir/Ritonavir [Poster]. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001, Poster Number 336Google Scholar
  8. Kearney BP, Flaherty JF, Sayre JR, Wolf JJ, and Coakley DF. A Multiple-Dose, Randomized, Crossover Drug Interaction Study between Tenofovir DF and Lamivudine or Didanosine. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001, Poster Number 337Google Scholar
  9. Margot NA, Johnson A, Cheng A, Coakley DF, and Miller MD. Final 48-Week Genotypic and Phenotypic Analyses of Study 907: Tenofovir DF (TDF) Added to Stable Background Regimens [poster abstract]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA 2002Google Scholar
  10. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, and De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections. Antivir Chem Chemother 1997; 8:1–23Google Scholar
  11. Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, M. Arimilli N, Kim CU, and De Clercq E Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)-9(2-phosphonylmethoxypropyl) Adenine in Mice. Antimicrob Agents Chemother 1998; 42:1568–1573PubMedGoogle Scholar
  12. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen S-S, Miller MD, Isaacson E, and Cheng AK. Tenofovir DF in Antiretroviral-experienced Patients: Results from a 48-week, Randomized, Double-blind Study. AIDS. 2002; 16:1257–1263PubMedCrossRefGoogle Scholar
  13. Shaw J-P, Sueoka CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, and Cundy KC. Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(Phosphonomethoxy)propyl]adenine (PMPA) in Dogs. Pharm Res 1997; 14:1824–1829PubMedCrossRefGoogle Scholar
  14. Sigel H. Metal Ion Complexes of Antivirally Active Nucleotide Analogues. Conclusions Regarding their Biological Action. Chem Soc Rev 2004; 33:191–200PubMedCrossRefGoogle Scholar
  15. Squires K, Pierone G, Berger D, Steinhart C, Bellos N, Becker SL, Chen SS, Miller MD, Coakley DF, and Cheng A. Tenofovir DF: A 48-week Final Analysis from a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Experienced Patients (Study 907). In: Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002 Poster Abstract 413-WGoogle Scholar
  16. VIREAD® (tenofovir disoproxil fumarate) Tablets. Package Insert. Gilead Sciences, Inc. Foster City, CA. June 2004Google Scholar
  17. Yuan L-C, Dahl TC, and Oliyai R. Effect of Carbonate Salts on the Kinetics of Acid-catalyzed Dimerization of Adefovir Dipivoxil. Pharm Res 2000; 17:1098–1103PubMedCrossRefGoogle Scholar
  18. Yuan L-C, Dahl TC, and Oliyai R. Degradation Kinetics of Oxycarbonyloxymethyl Prodrugs of Phosphonates in Solution. Pharm Res 2001; 18:234–237PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Maria Fardis
    • 1
  • Reza Oliyai
    • 1
  1. 1.Gilead Sciences Inc.Foster CityUSA

Personalised recommendations